WO2000000161A3 - Methods for identification of tef-3 interacting factors - Google Patents

Methods for identification of tef-3 interacting factors Download PDF

Info

Publication number
WO2000000161A3
WO2000000161A3 PCT/US1999/014829 US9914829W WO0000161A3 WO 2000000161 A3 WO2000000161 A3 WO 2000000161A3 US 9914829 W US9914829 W US 9914829W WO 0000161 A3 WO0000161 A3 WO 0000161A3
Authority
WO
WIPO (PCT)
Prior art keywords
tef
methods
identification
interacting factors
further provides
Prior art date
Application number
PCT/US1999/014829
Other languages
French (fr)
Other versions
WO2000000161A2 (en
Inventor
Michael Howard Tindal
Richard Lee Wang
Original Assignee
Procter & Gamble
Michael Howard Tindal
Richard Lee Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble, Michael Howard Tindal, Richard Lee Wang filed Critical Procter & Gamble
Priority to AU50866/99A priority Critical patent/AU5086699A/en
Priority to CA002332121A priority patent/CA2332121A1/en
Priority to JP2000556746A priority patent/JP2002519008A/en
Priority to IL14005899A priority patent/IL140058A0/en
Priority to EP99935376A priority patent/EP1089794A2/en
Publication of WO2000000161A2 publication Critical patent/WO2000000161A2/en
Priority to NO20006198A priority patent/NO20006198L/en
Publication of WO2000000161A3 publication Critical patent/WO2000000161A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides in vivo or in vitro methods for screening for inhibitors of TEF-3 activity. The invention further provides methods for identifying TEF-3 interacting factors. The invention still further provides methods for treating matrix metalloprotease-mediated diseases, including those of the musculoskeletal system, and cardiac muscle, as well as growth related skeletal diseases.
PCT/US1999/014829 1998-06-30 1999-06-30 Methods for identification of tef-3 interacting factors WO2000000161A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU50866/99A AU5086699A (en) 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity
CA002332121A CA2332121A1 (en) 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity
JP2000556746A JP2002519008A (en) 1998-06-30 1999-06-30 Methods for inhibiting TEF-3 activity
IL14005899A IL140058A0 (en) 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity
EP99935376A EP1089794A2 (en) 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity
NO20006198A NO20006198L (en) 1998-06-30 2000-12-06 Methods for inhibiting TEF-3 activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9131898P 1998-06-30 1998-06-30
US60/091,318 1998-06-30

Publications (2)

Publication Number Publication Date
WO2000000161A2 WO2000000161A2 (en) 2000-01-06
WO2000000161A3 true WO2000000161A3 (en) 2001-01-04

Family

ID=22227169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/014829 WO2000000161A2 (en) 1998-06-30 1999-06-30 Methods for identification of tef-3 interacting factors

Country Status (7)

Country Link
EP (1) EP1089794A2 (en)
JP (1) JP2002519008A (en)
AU (1) AU5086699A (en)
CA (1) CA2332121A1 (en)
IL (1) IL140058A0 (en)
NO (1) NO20006198L (en)
WO (1) WO2000000161A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001906A1 (en) * 2001-06-27 2003-01-09 Takeda Chemical Industries, Ltd. Method of constructing joint disease model animal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006277A1 (en) * 1995-08-09 1997-02-20 The Regents Of The University Of California Methods for drug screening
WO1998019158A1 (en) * 1996-10-31 1998-05-07 Merck & Co., Inc. Assay and cell line for the identification of growth hormone mimetics
WO1998037235A1 (en) * 1997-02-24 1998-08-27 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
US5824794A (en) * 1994-12-23 1998-10-20 Syntex (U.S.A.) Inc. Human stromelysin-1 promoter

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824794A (en) * 1994-12-23 1998-10-20 Syntex (U.S.A.) Inc. Human stromelysin-1 promoter
WO1997006277A1 (en) * 1995-08-09 1997-02-20 The Regents Of The University Of California Methods for drug screening
WO1998019158A1 (en) * 1996-10-31 1998-05-07 Merck & Co., Inc. Assay and cell line for the identification of growth hormone mimetics
WO1998037235A1 (en) * 1997-02-24 1998-08-27 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DESOUZA S. ET AL.: "A novel nerve growth factor-responsive element in the stromelysin-1 (transin) gene that is necessary and sufficient for gene expression in PC12 cells.", J BIOL CHEM 1995 APR 21;270(16):9106-14, XP002142993 *
GUPTA KALPANA ET AL: "Mmip1: A novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.", ONCOGENE MARCH 5, 1998, vol. 16, no. 9, 5 March 1998 (1998-03-05), pages 1149 - 1159, XP000916801, ISSN: 0950-9232 *
GUPTA MP. ET AL.: "Catecholamines and cardiac growth.", MOL CELL BIOCHEM 1996 OCT-NOV;163-164:203-10, XP002142995 *
JACQUEMIN P. ET AL.: "A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain.", J BIOL CHEM 1996 SEP 6;271(36):21775-85, XP002142991 *
JANUSZ MJ. ET AL.: "Human chondrosarcoma cells stably transfected with a stromelysin (MMP-3) promoter reporter construct provide a method of assessing transcriptional inhibitors.", INFLAMM RES 1997 AUG;46 SUPPL 2:S159-60, XP000916871 *
KIRSTEIN M. ET AL.: "Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene.", J BIOL CHEM 1996 JUL 26;271(30):18231-6, XP000916859 *
SUZUKI HIDEAKI ET AL: "Activation of the laminin gamma1 chain gene promoter through the bcn-1 element by two unrelated transcription factors, TFE3 and RTEF-1.", 32ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY;MIAMI BEACH, FLORIDA, USA; NOVEMBER 1-8, 1999, vol. 10, no. PROGRAM AND ABSTR. ISSUE, 1999, Journal of the American Society of Nephrology Sept., 1999, pages 581A, XP000916744, ISSN: 1046-6673 *
YANG E ET AL: "BAD, A HETERODIMERIC PARTNER FOR BCL-XL AND BCL-2. DISPLACES BAX AND PROMOTES CELL DEATH", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 80, no. 2, 27 January 1995 (1995-01-27), pages 285 - 291, XP002053602, ISSN: 0092-8674 *
YOCKEY CE. ET AL.: "cDNA cloning and characterization of murine transcriptional enhancer factor-1-related protein 1, a transcription factor that binds to the M-CAT motif.", J BIOL CHEM 1996 FEB 16;271(7):3727-36, XP002142992 *
ZOU YIMIN ET AL: "CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway.", DEVELOPMENT (CAMBRIDGE) 1997, vol. 124, no. 4, 1997, pages 793 - 804, XP000863100, ISSN: 0950-1991 *

Also Published As

Publication number Publication date
NO20006198D0 (en) 2000-12-06
EP1089794A2 (en) 2001-04-11
NO20006198L (en) 2001-02-28
AU5086699A (en) 2000-01-17
JP2002519008A (en) 2002-07-02
WO2000000161A2 (en) 2000-01-06
CA2332121A1 (en) 2000-01-06
IL140058A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
MXPA05004225A (en) Neutralizing antibodies against gdf-8 and uses therefor.
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
WO2003027248A8 (en) Antibody inhibitors of gdf-8 and uses thereof
WO2002099083A3 (en) Gfats as modifiers of the p53 pathway and methods of use
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
IT1303790B1 (en) "INTERNAL-EXTERNAL ELECTROMYOGRAPHIC DETECTION IMPLANTABLE EQUIPMENT, IN PARTICULAR FOR THE IN VIVO STUDY OF THE ACTIVITY
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
GB2319725B (en) Extracting particles produced by the treating of human or animal nails
AU2002365365A1 (en) Metal complex compounds
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
EP1254260A4 (en) Methods for diagnosing and treating heart disease
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
WO2000000161A3 (en) Methods for identification of tef-3 interacting factors
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
EP1255110A3 (en) Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
WO1999050671A3 (en) Toso as a target for drug screening
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2003028537A3 (en) Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
WO2003006611A3 (en) GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
WO2003020294A8 (en) Aromatase marking

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 508436

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 140058

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00396/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2332121

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999935376

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 556746

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 50866/99

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999935376

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09720166

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999935376

Country of ref document: EP